

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names (Rec. INN): List 38

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–73) and Recommended (1–35) International Nonproprietary Names can be found in *Cumulative List No. 9, 1996*.

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES (DCI Rec): Liste 38

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9)] les dénominations ci-dessous sont mises à l'étude par l'Organisation mondiale de la Santé en tant que dénominations communes internationales proposées. L'inclusion d'une dénomination dans les listes de DCI proposées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–73) et recommandées (1–35) dans la *Liste récapitulative No. 9, 1996*.

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS (DCI Rec.): Lista 38

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–73) y Recomendadas (1–35) se encuentran reunidas en *Cumulative List No. 9, 1996*.

MODIFICATION

This is to inform you that WHO will henceforth publish lists of recommended INNs **twice a year**.

This new measure is intended to provide information as soon as possible on the names that have reached the status of recommended INNs.

MODIFICATION

L'OMS publiera désormais les listes des DCI recommandées **deux fois par an**.

Cette nouvelle mesure est destinée à informer les lecteurs dès que possible au sujet des dénominations ayant atteint le statut de DCI recommandée.

MODIFICACION

De ahora en adelante, la OMS publicará **dos veces por año** las listas de DCI recomendadas.

Con esta nueva medida se quiere facilitar lo antes posible la información sobre las denominaciones a las que se ha asignado la condición de DCI recomendadas.

Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada

abacavirum

abacavir

(1*S*,4*R*)-4-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]-2-cyclopentene-1-methanol


abacavir

[(1*S*,4*R*)-4-[2-amino-6-(cyclopropylamino)-9*H*-purin-9-yl]cyclopent-2-ényl]méthanol

abacavir

(1*S*,4*R*)-4-[2-amino-6-(ciclopropilamino)-9*H*-purin-9-il]-2-ciclopenteno-1-metanol

C₁₄H₁₈N₆O



almotriptanum

almotriptan

1-[[[3-[2-(dimethylamino)ethyl]indol-5-yl]methyl]sulfonyl]pyrrolidine


almotriptan

1-[[[3-[2-(diméthylamino)éthyl]-1*H*-indol-5-yl]méthyl]sulfonyl]pyrrolidine

almotriptán

1-[[[3-[2-(dimetilamino)etil]indol-5-il]metil]sulfonyl]pirrolidina

C₁₇H₂₅N₃O₂S



bamaquimastum


bamaquimast

3-(3-hydroxypropyl)-1-propyl-2(1*H*)-quinoxalinone methylcarbamate (ester)

bamaquimast

méthylcarbamate de 3-(3-oxo-4-propyl-3,4-dihydroquinoxalin-2-yl)propyle

bamaquimast

metilcarbamato(éster) de 3-(3-hidroxipropil)-1-propil-2(1*H*)-quinoxalinaC₁₆H₂₁N₃O₃**basiliximabum**

basiliximab

immunoglobulin G 1 (human-mouse monoclonal CHI621 heavy chain anti-human interleukin 2 receptor), disulfide with human-mouse monoclonal CHI621 light chain, dimer

basiliximab

immunoglobuline G 1 (chaîne lourde de l'anticorps monoclonal chimérique homme-souris CHI621 dirigé contre le récepteur humain de l'interleukine 2), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal chimérique homme-souris CHI621

basiliximab

inmunoglobulina G 1 (cadena pesada del anticuerpo monoclonal quimérico hombre-ratón CHI621 dirigido contra el receptor humano de la interleuquina 2), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal quimérico hombre-ratón CHI621

betadexum

betadex


β-cyclodextrin

bétadex

β-cyclodextrine

betadex

β-ciclodextrina

C₄₂H₇₀O₃₅

bimoclomolum


bimoclomol

 (\pm) -*N*-(2-hydroxy-3-piperidinopropoxy)nicotinimidoyl chloride

bimoclomol

chlorure de *N*-[*(2RS)*-2-hydroxy-3-(pipéridin-1-yl)propoxy]pyridin-3-carboximidoyle

bimoclomol

cloruro de (\pm) -*N*-(2-hidroxi-3-piperidinopropoxi)nicotinimidoilC₁₄H₂₀ClN₃O₂**blonanserinum**


blonanserin

2-(4-ethyl-1-piperazinyl)-4-(*p*-fluorophenyl)-5,6,7,8,9,10-hexahydrocyclo=octa[*b*]pyridine

blonansérine

2-(4-éthylpipérazin-1-yl)-4-(4-fluorophényl)-5,6,7,8,9,10-hexahydrocyclo=octa[*b*]pyridine

blonanserina

2-(4-etil-1-piperazinil)-4-(*p*-fluorofenil)-5,6,7,8,9,10-hexahidrociclo=octa[*b*]piridinaC₂₃H₃₀FN₃**brasofensinum**


brasofensine

3 β -(3,4-dichlorophenyl)-1 α H,5 α H-tropane-2 α -carboxaldehyde (*E*)-(O-methyloxime)

brasofensine

(1*R*,2*R*,3*S*,5*S*)-3-(3,4-dichlorophényl)-8-méthyl-8-azabicyclo[3.2.1]octane-2-carbaldéhyde (*E*)-*O*-méthyloxime

brasofensina

3 β -(3,4-diclorofenil)-1 α H,5 α H-tropano-2 α -carboxaldehído (*E*)-(O-metiloxima)C₁₆H₂₀Cl₂N₂O

brinzolamidum


brinzolamide

(R)-4-(ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2*H*-thieno[3,2-*e*]-1,2-thiazine-6-sulfonamide 1,1-dioxide

brinzolamide

(4R)-4-(éthylamino)-2-(3-méthoxypropyl)-3,4-dihydro-2*H*-thiéno[3,2-*e*]-1,2-thiazine-6-sulfonamide 1,1-dioxyde

brinzolamida

(R)-4-(etilamino)-3,4-dihidro-2-(3-metoxipropil)-2*H*-tieno[3,2-*e*]-1,2-tiazina-6-sulfonamida 1,1-dióxidoC₁₂H₂₁N₃O₅S₃**cevimelinum**


cevimeline

 (\pm) -*cis*-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine]

céviméline

(3RS,2'RS)-2'-méthylspiro[1-azabicyclo[2.2.2]octane-3,5'-[1,3]oxathiolane]

cevimelina

 (\pm) -*cis*-2-metilespiro[1,3-oxatiolano-5,3'-quinuclidina]C₁₀H₁₇NOS**cizolirtinum**


cizolirtine

 (\pm) -5-[α -[2-(dimethylamino)ethoxy]benzyl]-1-methylpyrazole

cizolirtine

N,N-diméthyl-2-[(*RS*)-(1-méthyl-1*H*-pyrazol-5-yl)phénylméthoxy]éthanamine

cizolirtina

 (\pm) -5-[α -[2-(dimetilamino)etoxi]bencil]-1-metilpirazolC₁₅H₂₁N₃O

dalcotidinum


dalcotidine

1-ethyl-3-[3-[(α -piperidino-*m*-tolyl)oxy]propyl]urea

dalcotidine

1-éthyl-3-[3-[3-[(pipéridin-1-yl)méthyl]phénoxy]propyl]urée

dalcotidina

1-etil-3-[3-[(α -piperidino-*m*-tolil)oxi]propil]ureaC₁₈H₂₉N₃O₂**daniplestimum**

daniplestim

14-L-alanine-18-L-isoleucine-25-L-histidine-29-L-arginine-32-L-asparagine-37-L-proline-42-L-serine-45-L-methionine-51-L-arginine-55-L-threonine-59-L-leucine-62-L-valine-67-L-histidine-69-L-glutamic acid-73-glycine-76-L-alanine-79-L-arginine-82-L-glutamine-87-L-serine-93-L-serine-98-L-isoleucine-101-L-alanine-105-L-glutamine-109-L-glutamic acid-116-L-valine-120-L-glutamine-123-L-glutamic acid-14-125-interleukin 3 (human clone D11 reduced)

daniplestim

[14-L-alanine-18-L-isoleucine-25-L-histidine-29-L-arginine-32-L-asparagine-37-L-proline-42-L-sérine-45-L-méthionine-51-L-arginine-55-L-thréonine-59-L-leucine-62-L-valine-67-L-histidine-69-acide L-glutamique-73-glycine-76-L-alanine-79-L-arginine-82-L-glutamine-87-L-sérine-93-L-sérine-98-L-isoleucine-101-L-alanine-105-L-glutamine-109-acide L-glutamique-116-L-valine-120-L-glutamine-123-acide L-glutamique]-14-125-interleukin 3 (clone humain D11 précurseur de la partie protéique réduite)

daniplestim

[14-L-alanina-18-L-isoleucina-25-L-histidina-29-L-arginina-32-L-asparagina-37-L-prolina-42-L-serina-45-L-metionina-51-L-arginina-55-L-treonina-59-L-leucine-62-L-valina-67-L-histidina-69-ácido L-glutámico-73-glicina-76-L-alanina-79-L-arginina-82-L-glutamina-87-L-serina-93-L-serina-98-L-isoleucina-101-L-alanina-105-L-glutamina-109-ácido L-glutámico-116-L-valina-120-L-glutamina-123-ácido L-glutámico]-14-125-interleuquina 3 (clon humano D11 precursor de la fracción proteica reducida)

C₅₆₄H₉₀₉N₁₆₁O₁₆₆S₅

```

ANCSIMIDEI  IHHLKRPPNP  LLDPNLNLSE  DMDILMERNL
RTPNLLAFVR  AVKHLENASG  IEAILRNLQP  CLPSATAAPS
RHPIIIKAGD  WQEFREKLTf  YLVTLEQAQE  QQ

```

dexefaroxanum

dexefaroxan


(+)-(*R*)-2-(2-ethyl-2,3-dihydro-2-benzofuranyl)-2-imidazoline

dexéfaroxan

(+) -2-[(2*R*)-2-éthyl-2,3-dihydrobenzofuran-2-yl]-4,5-dihydro-1*H*-imidazole

dexefaroxán

(+)-(*R*)-2-(2-etil-2,3-dihidro-2-benzofuranil)-2-imidazolina

C₁₃H₁₆N₂O**elacridarum**


elacridar

4'-[2-(3,4-dihydro-6,7-dimethoxy-2(1*H*)-isoquinolyl)ethyl]-5-methoxy-9-oxo-4-acridancarboxanilide

élaacidar

N-[4-[2-(6,7-diméthoxy-3,4-dihydroisoquinoléin-2(1*H*)-yl)éthyl]phényl]-5-méthoxy-9-oxo-9,10-dihydroacridine-4-carboxamide

elacridar

4'-[2-(3,4-dihidro-6,7-dimetoxi-2(1*H*)-isoquinolil)etil]-5-metoxi-9-oxo-4-acridancarboxanilidaC₃₄H₃₃N₃O₅**eldacimibum**


eldacimibe

cyclic isopropylidene [(3,5-di-*tert*-butyl-4-hydroxyanilino)[hexyl=(*p*-neopentylbenzyl)amino]methylene]malonate

eldacimibe

5-[[[3,5-bis(1,1-diméthyléthyl)-4-hydroxyphényl]amino][[4-(2,2-diméthylpropyl)benzyl]hexylamino]méthylène]-2,2-diméthyl-1,3-dioxane-4,6-dione

eldacimiba

[(3,5-di-*tert*-butil-4-hidroxianilino)[hexil(*p*-neopentilbencil)amino]=metileno]malonato cíclico de isopropilidenoC₃₉H₅₈N₂O₅

eperezolidum


eperezolid

N-[[*(S)*-3-[3-fluoro-4-(4-glycoloyl-1-piperazinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]acetamide

épérezolide

N-[[*(5S)*-3-[3-fluoro-4-[4-(2-hydroxyacétyl)pipérazin-1-yl]phényl]-2-oxooxazolidin-5-yl]méthyl]acétamide

eperezolida

N-[[*(S)*-3-[3-fluoro-4-(4-glicoloil-1-piperazinil)fenil]-2-oxo-5-oxazolidinil]metil]acetamidaC₁₈H₂₃FN₄O₅**esatenololum**


esatenolol

2-[*p*-[(2*S*)-2-hydroxy-3-(isopropylamino)propoxy]phenyl]acetamide

ésaténolol

2-[4-[(2*S*)-2-hydroxy-3-[(1-méthyléthyl)amino]propoxy]phényl]acétamide

esatenolol

2-[*p*-[(2*S*)-2-hidroxi-3-(isopropilamino)propoxi]fenil]acetamidaC₁₄H₂₂N₂O₃**faralimomabum**

faralimomab

immunoglobulin G 1 (mouse monoclonal 64G12 γ 1-chain anti-human interferon receptor), disulfide with mouse monoclonal 64G12 light chain, dimer

faralimomab


immunoglobuline G 1 (chaîne γ 1 de l'anticorps monoclonal de souris (64G12) dirigé contre le récepteur humain des interférons de type I), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris 64G12

faralimomab


inmunoglobulina G 1 (cadena γ 1 del anticuerpo monoclonal de ratón (64G12) dirigido contra el receptor humano de los interferones de tipo I), dímero del disulfuro con la cadena ligera del anticuerpo monoclonal de ratón 64G12

gacyclidinum


gacyclidine	1-[<i>cis</i> -2-methyl-1-(2-thienyl)cyclohexyl]piperidine
gacyclidine	1-[(1 <i>RS</i> ,2 <i>SF</i>)-2-méthyl-1-(thiophén-2-yl)cyclohexyl]pipéridine
gaciclidina	1-[<i>cis</i> -2-metil-1-(2-tienil)ciclohexil]piperidina
	C ₁₆ H ₂₅ NS

**ganaxolonum**

ganaxolone	3 α -hydroxy-3-methyl-5 α -pregnan-20-one
ganaxolone	3 α -hydroxy-3-méthyl-5 α -prégnan-20-one
ganaxolona	3 α -hidroxi-3-metil-5 α -pregnan-20-ona
	C ₂₂ H ₃₆ O ₂

**hemoglobinum crosfumarilum**

hemoglobin crosfumaril	hemoglobin A ₀ (human $\alpha_2\beta_2$ tetrameric subunit), α -chain 99,99'-diamide with fumaric acid
hémoglobine crosfumaril	99,99'-diamide de la chaîne α de l'hémoglobine A ₀ (sous-unité tétramérique $\alpha_2\beta_2$ humaine) avec l'acide fumarique
hemoglobina crosfumarilo	99,99'-diamida de la cadena α de la hemoglobina A ₀ (subunidad tetramérica $\alpha_2\beta_2$ humana), con el ácido fumárico



indisetronum


indisetron

N-(3,9-dimethyl-*endo*-3,9-diazabicyclo[3.3.1]non-7-yl)-1*H*-indazole-3-carboxamide

indisétron

N-[(1*R*,5*S*,7*S*)-3,9-diméthyl-3,9-diazabicyclo[3.3.1]non-7-yl]-1*H*-indazole-3-carboxamide

indisetrón

N-(3,9-dimetil-*endo*-3,9-diazabicyclo[3.3.1]non-7-il)-1*H*-indazol-3-carboxamida
C₁₇H₂₃N₅O**insulinum aspartum**


insulin aspart

28^B-L-aspartic acid-insulin (human)

insuline asparte

[28^B-acide L-aspartique]insuline humaine

insulina asparta

28^B-L-ácido aspártico-insulina(humana)C₂₅₆H₃₈₁N₆₅O₇₉S₆**insulinum glarginum**


insulin glargine


21^A-glycine-30^{Ba}-L-arginine-30^{Bb}-L-arginineinsulin (human)

insuline glargine

[21^A-glycine]30^{Ba}-L-arginine-30^{Bb}-L-arginine-insuline humaine

insulina glargina

21^A-glicina-30^{Ba}-L-arginina-30^{Bb}-L-arginina-insulina (humana)C₂₆₇H₄₀₄N₇₂O₇₈S₆

iometopanium (¹²³I)iometopane (¹²³I)methyl 3β-(*p*-[¹²³I]iodophenyl)-1α_H,5α_H-tropane-2β-carboxylateiométopane (¹²³I)(1*R*,2*S*,3*S*,5*S*)-3-(4-[¹²³I]iodophényl)-8-méthyl-8-azabicyclo[3.2.1]octane-2-carboxylate de méthyleiometopano (¹²³I)3β-(*p*-[¹²³I]iodofenil)-1α_H,5α_H-tropano-2β-carboxilato de metiloC₁₆H₂₀¹²³INO₂**israpafantum**


israpafant

(±)-4-(*o*-chlorophenyl)-2-(*p*-isobutylphenethyl)-6,9-dimethyl-6*H*-thieno[3,2-*f*]-*s*-triazolo[4,3-*a*][1,4]diazepine

israpafant

(6*RS*)-4-(2-chlorophényl)-6,9-diméthyl-2-[2-[4-(2-méthylpropyl)phényl]éthyl]-6*H*-thiéno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazépine

israpafant

(±)-4-(*o*-chlorofenil)-2-(*p*-isobutilfenetil)-6,9-dimetil-6*H*-thieno[3,2-*f*]-*s*-triazolo[4,3-*a*][1,4]diazepinaC₂₈H₂₉ClN₄Sand enantiomer
et énantiomère
y enantiómero**keliximabum**

keliximab

immunoglobulin G 1 (human-Macaca monoclonal CE9.1 γ1-chain anti-human antigen CD 4), disulfide with human-Macaca monoclonal CE9.1 κ-chain, dimer

kéliximab

immunoglobuline G 1 (chaîne γ1 de l'anticorps monoclonal chimérique homme-macaque CE9.1 dirigé contre l'antigène CD 4 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal chimérique homme-macaque CE9.1

keliximab

inmunoglobulina G 1 (cadena γ1 del anticuerpo monoclonal quimérico hombre-macaco CE9.1 dirigido contra el antígeno CD4 humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal dimérico hombre-macaco CE9.1

lanoteplasum

lanoteplase

N-[*N*²-(*N*-glycyl-L-alanyl)-L-arginyl]-117-L-glutamine-245-L-methionine-(1-5)-(87-527)-plasminogen activator (human tissue-type protein moiety)

lanotéplase

N-[*N*²-(*N*-glycyl-L-alanyl)-L-arginyl]-[117-L-glutamine-245-L-méthionine]- (1-5)-(87-527)- activateur du plasminogène (type tissulaire humain, partie protéique)

lanoteplasa

N-[*N*²-(*N*-glicil-L-alanil)-L-arginil]-[117-L-glutamina-245-L-metionina]- (1-5)-(87-527)-activador del plasminógeno (tipo tisular humano, fracción proteica)

C₂₁₈₄H₃₃₂₃N₆₃₃O₆₆₆S₂₉

```

GARSYQVIDT  RATCYEDQGI  SYRGTWSTAE  SGAECTNWQS
SALAQKPYSG  RRPDAIRLGL  GNHNYCRNPD  RDSKPWCYVF
KAGKYSSEFC  STPACSEGENS  DCYFGNGSAY  RGTHSLTESG
ASCLPWNSMI  LIGKVYTAQN  PSAQALGLGK  HNYCRNPDGD
AKPWCHNLKN  RRLTWEYCDV  PSCSTCGLRQ  YSQPQFR IKG
GLFADIASHP  WQAAIFAKHR  RSPGERFLCG  GILISSCWIL
SAAHCFQERF  PPHHLTVILG  RTYRVVPGEE  EQKFEVEKYI
VHKEFDDDTY  DNDIALQLK  SDSSRCAQES  SVVRTVCLPP
ADLQLPDWTE  CELSGYGKHE  ALSPFYSERL  KEAHVRLYPS
SRCTSQHLLN  RTVTDNMLCA  GDTRSGGPQA  NLHDAÇQGDS
GGPLVCLNDG  RMTLVGI ISW  GLGCGQKDVP  GVYTKVTNYL
DWIRDNMRP

```

* binding sites of sugar chain

* sites de fixation de la chaîne osidique

* lugares de unión de la cadena osídica

lasinavirum

lasinavir


tert-butyl [(α S)- α -[(1*S*,3*R*)-1-hydroxy-3-[[[(1*S*)-1-[(2-methoxyethyl)carbamoyl]-2-methylpropyl]carbamoyl]-4-(2,3,4-trimethoxyphenyl)butyl]phenethyl]=carbamate

lasinavir

[(1*S*,2*S*,4*R*)-1-benzyl-2-hydroxy-5-[[[(1*S*)-1-[(2-méthoxyéthyl)carbamoyl]-2-méthylpropyl]amino]-5-oxo-4-(2,3,4-triméthoxybenzyl)pentyl]carbamate de 1,1-diméthyléthyle

lasinavir

[(α S)- α -[(1*S*,3*R*)-1-hidroxi-3-[[[(1*S*)-1-[(2-metoxietil)-carbamoil]-2-metilpropil]carbamoil]-4-(2,3,4-trimetoxifenil)butil]fenetil]carbamato de *tert*-butilo

$C_{35}H_{53}N_3O_9$ **ledoxantrone**


ledoxantrone

5-[(2-aminoethyl)amino]-2-[2-(diethylamino)ethyl]-2*H*[1]benzothiopyrano-[4,3,2-*cd*]indazol-8-ol

ledoxantrone

5-[(2-aminoéthyl)amino]-2-[2-(diéthylamino)éthyl]-2*H*[1]benzothiopyrano-4,3,2-*cd*]indazol-8-ol

ledoxantrona

5-[(2-aminoetil)amino]-2-[2-(diethylamino)etil]-2*H*[1]benzotiopirano-[4,3,2-*cd*]indazol-8-ol $C_{21}H_{27}N_5OS$ **linezolidum**


linezolid

N-[[*(S)*-3-(3-fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl]acetamide


linézolide

N-[[*(5S)*-3-[3-fluoro-4-(morpholin-4-yl)phényl]-2-oxooxazolidin-5-yl]méthyl]acétamide


linezolid

N-[[*(S)*-3-(3-fluoro-4-morfolinofenil)-2-oxo-5-oxazolidinil]metil]acetamida $C_{16}H_{20}FN_3O_4$ 

lintuzumabum lintuzumab	immunoglobulin G 1 (human-mouse monoclonal HuM195 γ 1-chain anti-human antigen CD 33), disulfide with human monoclonal HuM195 κ -chain, dimer
lintuzumab	immunoglobuline G 1 (chaîne légère γ 1 de l'anticorps monoclonal de souris humanisé HuM195 dirigé contre l'antigène CD 33 humain), dimère du disulfure avec la chaîne κ de l'anticorps monoclonal humain HuM195
lintuzumab	inmunoglobulina G 1 (cadena ligera γ 1 del anticuerpo monoclonal de ratón humanizado HuM195 dirigido contra el antígeno CD 33 humano), dímero del disulfuro con la cadena κ del anticuerpo monoclonal humano Hu195
metesindum metesind	4-[[α -[(2-aminobenz[<i>cd</i>]indol-6-yl)methylamino]- <i>p</i> -tolyl]sulfonyl]morpholine
métésind	4-[[4-[[[(2-aminobenz[<i>cd</i>]indol-6-yl)(méthyl)amino]méthyl]phényl]=sulfonyl]morpholine
metesind	4-[[α -[(2-aminobenz[<i>cd</i>]indol-6-il)metilamino]- <i>p</i> -tolil]sulfonyl]morfolina C ₂₃ H ₂₄ N ₄ O ₃ S



milfasartanum milfasartan	methyl 2-[[4-butyl-2-methyl-6-oxo-5-[<i>p</i> -(<i>o</i> -1 <i>H</i> -tetrazol-5-yl)phenyl]benzyl]-1(6 <i>H</i>)-pyrimidinyl]methyl]-3-thiophenecarboxylate
milfasartan	2-[[4-butyl-2-méthyl-6-oxo-5-[4-[2-(1 <i>H</i> -tétrazol-5-yl)phényl]bénzyl]pyrimidin-1(6 <i>H</i>)-yl]méthyl]thiophène-3-carboxylate de méthyle
milfasartán	2-[[4-butil-2-metil-6-oxo-5-[<i>p</i> -(<i>o</i> -1 <i>H</i> -tetrazol-5-ilfenil)benzil]-1(6 <i>H</i>)-pirimidinil]metil]-3-tiofenocarboxilato de metilo C ₃₀ H ₃₀ N ₆ O ₃ S




minalrestatum

minalrestat (\pm)-2-(4-bromo-2-fluorobenzyl)-6-fluorospiro[isoquinoline-4(1*H*),3'-pyrrolidine]-1,2',3,5'(2*H*)-tetrone

minalrestat (3'*RS*)-2-(4-bromo-2-fluorobenzyl)-6-fluorospiro[isoquinoléine-4(1*H*),3'-pyrrolidine]-1,2',3,5'(2*H*)-tétrone

minalrestat (\pm)-2-(4-bromo-2-fluorobencil)-6-fluoroespiro[isoquinolina-4(1*H*),3'-pirrolidin]-1,2',3,5'(2*H*)-tetrona

C₁₉H₁₁BrF₂N₂O₄


**nagrestipenum**

nagrestipen 26-L-alaninelymphokine MiP 1 α (human clone pAT464 macrophage inflammatory)

nagrestipen [26-L-alanine]lymphokine MiP 1 α (clone pAT464 de macrophage inflammatoire humain)

nagrestipen [26-L-alanina]linfoquina MiP 1 α (clon pAT464 de macrófago inflamatorio humano)


C₃₃₈H₅₁₆N₈₈O₁₀₈S₄

**nelfinavirum**

nelfinavir (3*S*,4*aS*,8*aS*)-*N*-*tert*-butyl-2-[(2*R*,3*R*)-3-(3,2-cresotamido)-2-hydroxy-4-(phenylthio)butyl]decahydro-3-isoquinolinecarboxamide

nelfinavir (3*S*,4*aS*,8*aS*)-*N*-(1,1-diméthyléthyl)-2-[(2*R*,3*R*)-2-hydroxy-3-(3-hydroxy-2-méthylbenzoyl)amino]-4-(phénylsulfanyl)butyl]décahydroisoquinoléine-3-carboxamide

nelfinavir (3*S*,4*aS*,8*aS*)-*N*-*terc*-butil-2-[(2*R*,3*R*)-3-(3,2-cresotamido)-2-hidroxi-4-feniltio)butil]decahidro-3-isoquinolinacarboxamida

C₃₂H₄₅N₃O₄S**nerelimomabum**

nerelimomab

immunoglobulin G 1 (mouse monoclonal BAYX1351 γ 1-chain anti-human tumor necrosis factor α), disulfide with mouse monoclonal BAYX1351 light chain, dimer

nérelimomab

immunoglobuline G 1 (chaîne γ 1 de l'anticorps monoclonal de souris BAYX1351 dirigé contre le facteur de nécrose tumorale α humain), dimère du disulfure avec la chaîne légère de l'anticorps monoclonal de souris BAYX1351

nerelimomab

immunoglobulina G 1 (cadena ligera mouse monoclonal BAYX1351 γ 1-chain anti-human tumor necrosis factor α), disulfide with mouse monoclonal BAYX1351 light chain, dimer

omiloxetinum

omiloxetine


4'-fluoro-2-[*trans*-4-(*p*-fluorophenyl)-3-[[3,4-(methylenedioxy)=phenoxy]methyl]piperidino]acetophenone

omiloxétine

2-[[*(3RS,4SR)*-3-[(1,3-benzodioxol-5-yloxy)méthyl]-4-(4-fluorophényl)]=pipéridin-1-yl]-1-(4-fluorophényl)éthanone

omiloxetino

4'-fluoro-2-[*trans*-4-(*p*-fluorofenil)-3-[[3,4-(metilenodioxo)]=fenoxi]metil]piperidino]acetofenona

C₂₇H₂₅F₂NO₄

and enantiomer
et l'énantiomère
y enantiomero

opratonii iodidum

opratonium iodide


iodure d'opratonium

ioduro de opratonio

trimethyl[3-(undecenamido)propyl]ammonium iodide

iodure de *N,N,N*-triméthyl-3-(undéc-10-énoylamino)propan-1-aminium

ioduro de trimetil[3-(undecenamido)propil]amonio

C₁₇H₃₅IN₂O**oprelvekinum**

oprelvekin

oprelvékine

oprelvekina

2-178-interleukin 11 (human clone pXM/IL-11)

2-178-interleukine 11 (clone humain pXM/IL-11)

2-178-interleuquina 11 (clon humano pXM/IL-11)

C₈₅₄H₁₄₁₁N₂₅₃O₂₃₅S₂

GPPPGPPRVS PDPRAELDST VLLTRSLLAD TRQLAAQLR
 KFPADGDHNL DSLPTLAMSA GALGALQLPG VLTRLRADL
 SYLRHVQWLR RAGGSSLKTL EPELGTLQAR LDRLLRRLQ
 LMSRLALPQP PPDPPAPPLA PPSSAWGGIR AAHAILGGL
 LTLDWAVRGL LLLKTRL

osutidinum

osutidine


osutidine

osutidina

(±)-*N*-[(*E*)-[(*p*,*β*-dihydroxyphenethyl)amino][[2-[[5-[(methylamino)=methyl]furfuryl]thio]ethyl]amino]methylene]methanesulfonamide

(*E*)-1-[(2*RS*)-2-hydroxy-2-(4-hydroxyphényl)éthyl]-3-[2-[[[5-[(méthylamino)=méthyl]-2-furyl]méthyl]sulfanyl]éthyl]-2-(méthylsulfonyl)guanidine

(±)-*N*-[(*E*)-[(*p*,*β*-dihidroxfenetil)amino][[2-[[5-[(metilamino)=metil]furfuril]tio]etil]amino]metileno]metanosulfonamida

C₁₉H₂₈N₄O₅S₂


and enantiomer
 et l'énantiomère
 y enantiomero

pelubiprofenum

pelubiprofen

pélubiprofène


pelubiprofeno

 (\pm) -*p*-[[*(E)*-2-oxocyclohexylidene]methyl]hydratropic acidacide (*2RS*)-2-[4-[[*(E)*-(2-oxocyclohexylidène)méthyl]phényl]propanoïqueácido(\pm)-*p*-[[*(E)*-2-oxociclohexiliden]metil]hidratrópicoC₁₆H₁₈O₃**pumaprazolum**

pumaprazole

pumaprazole


pumaprazol

methyl 2-[[[(2,3-dimethylimidazo[1,2-*a*]pyridin-8-yl)amino]methyl]-3-methylcarbanilate2-[[[(2,3-diméthylimidazo[1,2-*a*]pyridin-8-yl)amino]méthyl]-3-méthylphényl]carbamate de méthyle2-[[[(2,3-dimetilimidazo[1,2-*a*]piridin-8-il)amino]metil]-3-metilcarbanilato de metiloC₁₉H₂₂N₄O₂**quilostigminum**

quilostigmine

quilostigmine

quilostigmina

(3*aS*,8*aF*)-1,2,3,3*a*,8,8*a*-hexahydro-1,3*a*,8-trimethylpyrrolo[2,3-*b*]indol-5-yl 3,4-dihydro-2(1*H*)-isoquinolinecarboxylate3,4-dihydroisoquinoléine-2(1*H*)-carboxylate de (3*aS*,8*aF*)-1,3*a*,8-triméthyl-1,2,3,3*a*,8,8*a*-hexahydro-pyrrolo[2,3-*b*]indol-5-yle3,4-dihidro-2(1*H*)-isoquinolinacarboxilato de (3*aS*,8*aF*)-1,2,3,3*a*,8,8*a*-hexahidro-1,3*a*,8-trimetilpirrolo[2,3-*b*]indol-5-iloC₂₃H₂₇N₃O₂

retigabium


retigabine

ethyl 2-amino-4-[(*p*-fluorobenzyl)amino]carbanilate

rétigabine

[2-amino-4-[(4-fluorobenzyl)amino]phényl]carbamate d'éthyle

retigabina

2-amino-4-[(*p*-fluorobencil)amino]carbanilato de etiloC₁₆H₁₈FN₃O₂**sabcomelinum**


sabcomeline

(R)-3-quinuclidineglyoxylonitrile (*Z*)-(O)-methyloxime

sabcoméline

(Z)-2-[(3*R*)-1-azabicyclo[2.2.2]oct-3-yl]-2-(méthoxyimino)acétonitrile

sabcomelina

(R)-3-quinuclidinaglyoxilonitrilo (*Z*)-(O)-metiloximaC₁₀H₁₅N₃O**scopinastum**


scopinast

7-[3-[4-[bis(*p*-fluorophenyl)hydroxymethyl]piperidino]propoxy]-6-methoxycoumarin


scopinast

7-[3-[4-[bis(4-fluorophényl)hydroxyméthyl]pipéridin-1-yl]propoxy]-6-méthoxy-2*H*-chromén-2-one

escopinast

7-[3-[4-[bis(*p*-fluorofenil)hidroximetil]piperidino]propoxi]-6-metoxicumarinaC₃₁H₃₁F₂NO₅

soretolidum	
soretolide	2,6-dimethyl- <i>N</i> -(5-methyl-3-isoxazolyl)benzamide
sorétolide	2,6-diméthyl- <i>N</i> -(5-méthylisoxazol-3-yl)benzamide
soretolida	2,6-dimetil- <i>N</i> -(5-metil-3-isoxazolil)benzamida
	C ₁₃ H ₁₄ N ₂ O ₂



tasonerminum	
tasonermin	1-157-tumor necrosis factor alfa-1a (human)
tasonermina	1-157-facteur de nécrose tumorale humain alfa-1a
tasonermina	1-157-factor de necrosis tumoral alfa-1a (humano)
	C ₇₇₈ H ₁₂₂₅ N ₂₁₅ O ₂₃₁ S ₂

```

VRSSSRTPSD KPAHVVANP QAEGQLQWLN RRANALLAN
VELRDNQLVV PSEGLYLIYS QVLFKGGQCP STHVLLTHT
SRIAVSYQTK VNLLSAIKSP CQRETPEGAE AKPWYEPIY
GGVFQLEKGD RLSAEINRPD YLDFAESGQV YFGIIAL

```

technetium (^{99m}Tc) nofetumomabum merpentanum

technetium (^{99m} Tc) nofetumomab merpentan	immunoglobulin G 2b (mouse monoclonal NR-LU-10 Fab fragment anti-human tumor), disulfide with mouse monoclonal NR-LU-10 κ-chain, [N,N'-[(2-formylethyl)ethylene]bis[2-mercaptoacetamido]](4-)-N,N',S,S']oxo=[^{99m} Tc]technetate(1-) conjugate
technétium (^{99m} Tc) nofétumomab merpentan	immunoglobuline G 2b (fragment Fab de l'anticorps monoclonal de souris NR-LU-10 dirigé contre une tumeur humaine), disulfure avec la chaîne κ de l'anticorps monoclonal de souris NR-LU-10 conjuguée avec l'oxo-[[N,N'-[1-(3-oxopropyl)éthane-1,2-diy]]bis[2-sulfanylacétamido]](4-)-N,N',S,S']=[^{99m} Tc]technétate(1-)
tecnecio (^{99m} Tc) nofetumomab merpentán	inmunoglobulina G 2b (fragmento Fab del anticuerpo monoclonal de ratón NR-LU-10 dirigido contra un tumor humano), disulfuro con la cadena κ del anticuerpo monoclonal de ratón NR-LU-10 conjugado con el oxo-[[N,N'-[1-(3-oxopropil)etano-1,2-dii]]bis[2-sulfanilacetamido]](4-)-N,N',S,S']=[^{99m} Tc]tecnecato(1-)

temiverinum


temiverine

4-(diethylamino)-1,1-dimethyl-2-butynyl (\pm)- α -phenylcyclohexaneglycolate

témivérine

(2*RS*)-2-cyclohexyl-2-hydroxy-2-phénylacétate de 4-(diéthylamino)-1,1-diméthylbut-2-ynyle

temiverina

(\pm)- α -fenilciclohexanoglicolato de 4-(dielamino)-1,1-dimetil-2-butiniloC₂₄H₃₅NO₃**ticolubantum**

ticolubant


(E)-6-[[[(2,6-dichlorophenyl)thio]methyl]-3-(phenethoxy)-2-pyridineacrylic acid

ticolubant

acide (E)-3-[6-[[[(2,6-dichlorophényl)sulfany]méthyl]-3-(2-phényléthoxy)=pyridin-2-yl]prop-2-énoïque

ticolubant

ácido (E)-6-[[[(2,6-diclorofenil)tio]metil]-3-(fenetiloxi)-2-piridinacrílico

C₂₃H₁₉Cl₂NO₃S**valsopodarum**


valsopodar

cyclo[[[(2*S*,4*R*,6*E*)-4-methyl-2-(methylamino)-3-oxo-6-octenoyl]-L-valyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl-L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl]

valsopodar

cyclo[L-alanyl-D-alanyl-N-méthyl-L-leucyl-N-méthyl-L-leucyl-N-méthyl-L-valyl-[(2*S*,4*R*,6*E*)-4-méthyl-2-(méthylamino)-3-oxooct-6-énoyl]-L-valyl-N-méthylglycyl-N-méthyl-L-leucyl-L-valyl-N-méthyl-L-leucyl]

valsopodar

ciclo[[[(2*S*,4*R*,6*E*)-4-metil-2-(metilamino)-3-oxo-6-octenoil]-L-valil-N-metilglicil-N-metil-L-leucil-L-valil-N-metil-L-leucil-L-alanil-D-alanil-N-metil-L-leucil-N-metil-L-leucil-N-metil-L-valil]C₆₃H₁₁₁N₁₁O₁₂

vedaclidinum

vedaclidine


(S)-3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]quinuclidine

védaclidine

(3S)-3-[4-(butylsulfanyl)-1,2,5-thiadiazol-3-yl]-1-azabicyclo[2.2.2]octane

vedaclidina

(S)-3-[4-(butiltio)-1,2,5-tiadiazol-3-il]quinuclidina

 $C_{13}H_{21}N_3S_2$ 

MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES

Dénominations communes internationales recommandées (DCI Rec.): Liste 30

(Informations pharmaceutiques OMS, Vol. 4, No.3, 1990)

- | | | |
|-------|-------------------------|---|
| p. 14 | saruplasum
saruplase | <i>remplacer la description par:</i>
pro-urokinase (activateur d'enzyme) (fraction protéique issue du clone humain pUK4/pUK18), non-glycosylée |
|-------|-------------------------|---|

Dénominations communes internationales recommandées (DCI Rec.): Liste 33

(Informations pharmaceutiques OMS, Vol. 7, No.3, 1993)

- | | | |
|------|-----------------------------|--|
| p. 6 | nasaruplasum
nasaruplase | <i>remplacer la description par:</i>
pro-urokinase (activateur d'enzyme) (fraction protéique issue du clone humain pA3/pD2/pF1), glycosylée |
|------|-----------------------------|--|

Pour toutes modifications apportées aux **Dénominations communes internationales recommandées (DCI Rec.): Listes 34-37** voir page 181, section *AMENDMENTS TO PREVIOUS LISTS*.

MODIFICACIONES A LAS LISTAS ANTERIORES

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 30

(Información Farmacéutica, OMS, Vol. 4, No. 3, 1990)

- | | | |
|-------|-------------------------|--|
| p. 13 | saruplasum
saruplase | <i>sustituyase la descripción por la siguiente:</i>
prouroquinasa (activador de enzima) (fracción proteica procedente del clon humano pUK4/pUK18), no glucosilada |
|-------|-------------------------|--|

Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 33

(Información Farmacéutica, OMS, Vol. 7, No. 3, 1993)

- | | | |
|------|-----------------------------|--|
| p. 6 | nasaruplasum
nasaruplase | <i>sustituyase la descripción por la siguiente:</i>
prouroquinasa (activador de enzima) (fracción proteica procedente del clon humano pA3/pD2/pF1), glucosilada |
|------|-----------------------------|--|

Para cualquier modificación de las **Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Listas 34-37** vease página 181, sección *AMENDMENTS TO PREVIOUS LISTS*.

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la *Procédure à suivre en vue de choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes impaires des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en los números impares de las listas de DCI propuestas.

